Jurgi Camblong - 18 Mar 2026 Form 3 Insider Report for SOPHiA GENETICS SA (SOPH)

Role
Chief Executive Officer, Director
Signature
/s/ Elimara Brunetto as Attorney-in- Fact for Jurgi Camblong
Issuer symbol
SOPH
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 09:46:26 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Camblong Jurgi Chief Executive Officer, Director C/O SOPHIA GENETICS SA, LA PIECE 12, ROLLE, SWITZERLAND /s/ Elimara Brunetto as Attorney-in- Fact for Jurgi Camblong 18 Mar 2026 0002007050

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SOPH Ordinary Shares 3,307,325 18 Mar 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 100,000 $3.16 Direct F3
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 29,000 $4.01 Direct F3
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 181,500 $4.24 Direct F3
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 556,604 $18.00 Direct F3
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 1,096,654 $4.72 Direct F4
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 1,143,293 $4.96 Direct F5
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 1,005,682 $3.29 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 616,351 ordinary shares issuable upon settlement of four restricted stock unit ("RSU") grants. Each RSU represents a contingent right to receive one ordinary share of the Issuer, vesting subject to the Reporting Person's continued service with the Issuer, as follows: (i) 19,938 ordinary shares from a May 18, 2022 grant vesting in equal monthly installments through May 18, 2026; (ii) 223,215 ordinary shares from an April 3, 2023 grant vesting in equal quarterly installments through April 3, 2027; (iii) 145,575 ordinary shares from an April 2, 2024 grant vesting in equal quarterly installments through April 2, 2028; and (iv) 227,623 ordinary shares from an April 2, 2025 grant, with 50% vesting on April 2, 2026 and the remainder vesting in equal quarterly installments through April 2, 2027.
F2 891,320 ordinary shares have been pledged pursuant to lending arrangements.
F3 The share options are fully vested and exercisable.
F4 The share option vests and becomes exercisable as to 25% of the ordinary shares on April 3, 2024, and then in equal monthly installments through April 3, 2027.
F5 The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2025, and then in equal monthly installments through April 2, 2028.
F6 The share option vests and becomes exercisable as to 50% of the ordinary shares on April 2, 2026, and then in equal monthly installments through April 2, 2027.

Remarks:

Exhibit list - Exhibit 24 - Power of Attorney